Clinical Trial Update: A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety, tolerability, and blood levels of PF-03654746 in Alzheimer's disease was terminated, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• PF-03654746

Snippet

Sponsor: Pfizer | Conditions: Alzheimer's Disease | Phase 1 | Status: TERMINATED | Results posted: 2014-06-04